Appetite Regulation and Mycoprotein

N/ACompletedNCT02053025

Imperial College London52 enrolled

Overview

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Appetite Energy Intake

Interventions

mycoproteinDIETARY_SUPPLEMENT

control proteinDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females between the ages of 18 and 65 * body mass index (BMI) 25-32kg/m2 * Weight stable over the past 6 months * No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels. * No paracetamol or other analgesic in the previous 48 hours * A score of \<2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ) * A score of \<2 in the SCOFF questionnaire Exclusion Criteria: * Persons outside the age and BMI ranges stated above * Pregnant and lactating women * Weight variation of greater than 5% in the last 6 months * Any diagnosed major illness * Any paracetamol or analgesic intake in the last 48 hours * Diagnosed eating disorder * Allergy to mycoprotein or mushrooms * Regular consumption of Quorn products * Dislike of any of the test foods or drinks * A score of \>2.5 in the Dutch Eating Behaviour questionnaire * A score of 2 or more in the SCOFF questionaire

Locations (1)

Imperial College NIHR CRF

London, United Kingdom

Outcomes

Primary Outcomes

Energy intake at ad-libitum meal

Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.

Time frame: upon completion of all participants, expected timeframe: 2 years

Secondary Outcomes

Glucagon-like peptide-1 (GLP-1)

Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

Time frame: upon completion of all participants, expected at 2 years

peptide tyrosine-tyrosine (PYY) levels

Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

Time frame: upon completion of all participants, expected at 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.